ABSTRACT Sera from 30 patients with astrocytoma were tested for antibody reacting with cell surface antigens of cultured autologous astrocytoma cells. Ten percent of the patients had antibody detectable by mixed hemacsorpt on assays, S50% by immune adherence and proteinA'assaysand 100% by anti-C3-mixed hemadsorption assays. Absorption analysis of reactive sera with autologous, allogeneic, and xenogeneic cells permitted the definition of three classes of astrocytoma cell surface antigens. Class I antigens showed an absolute restriction to autologous astrocytoma cells. Class II antigens were shared by all astrocytomas tested and could be detected also on neuroblastoma, sarcoma, and some (but not all) melanoma cell lines; these antigens were not found on cell lines derived from carcinomas or normal tissues. Class III antigens were widely distributed on cultured normal and malignant cells of human and animal origin. In this series, sera from 2 patients recognized class I antigens, 4 patients' serum recognized class II antigens, and 13 atients' sera recognized class III antigens. Absorption tests have shown that the AJ (class II) antigen of astrocytoma is serologically related to the previously described AH (class II) antigen of melanoma; in tests of nine melanoma cell lines, there was a correspondence between the AJ and AH phenotypes. This method of autologouslyping provides a way to classify the cell surface antigens of astrocytomas and to assess the clinical significance of humoral immunity to these antigens.
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An underlying assumption of much work in cancer immunology is that cancer cells can be distinguished from normal cells by the presence of distinctive antigens on the surface of the cancer cells. The evidence supporting this assumption comes primarily from transplantation studies in inbred mice and rats with tumors induced by chemical carcinogens, such as methylcholanthrene, or by viruses, such as polyoma. The repeated demonstration that these tumors are immunogenic in syngeneic hosts represents the cornerstone of the field of cancer immunology.
Despite the enormous literature that has centered on the question of tumor-specific antigens of human cancers, the existence of such antigens must still be considered in the realm of speculation, not fact. The general impression by many in the field of tumor immunology as well as those in related fields, that tumor-specific antigens have been demonstrated in many types of human cancers, is simply not justified. The critical issue with regard to tumor-specific antigens is, of course, the question of specificity, and demonstrating the specificity of a serological or cell-mediated reaction is orders of magnitude easier in the mouse than in man. Lacking inbred mouse strains, hyperimmune antisera, and transplanted tumor cell lines with defined antigenicity, the human cancer serologist seeking evidence for tumor-specific antigens is faced with an exceedingly difficult task. Heteroimmune sera prepared against human cancer cells that at first have the appearance of tumor specificity have in every instance, when analyzed sufficiently, turned out to be directed against normal cellular products, either present in higher concentrations in tumor cells or found in a restricted normal cell population. Surveys of human sera for reactivity with cell surface antigens of allogeneic tumor cells, the basis of a vast number of reports in the literature, are rarely, if ever, interpretable in terms of tumor-specific reactions, because the unknown participation of alloantibodies in the reactions observed is extremely difficult to exclude.
To develop as unambiguous a serological typing system as possible, we turned several years ago to analyzing autologous serum reactivity to cell surface antigens of human tumors (1) (2) (3) (4) . In the case of solid tumors, the need for target cells that can be repeatedly tested has restricted our studies to tumor types that can be adapted to tissue culture growth with some degree of regularity-e.g., melanoma, renal cancer, and astrocytoma. Absorption tests with normal and malignant cells from autologous, allogeneic, and xenogeneic sources have provided the way to analyze the specificity of autologous reactions and to determine the distribution of the detected antigen on various cell types. By applying this approach to the study of malignant melanoma, the most compelling evidence to date for the existence of tumor-specific antigens in human cancer has been obtained (1, 2) . We now report the results of a comparable serological analysis of human astrocytomas.
MATERIALS AND METHODS Tissue culture procedures
Astrocytomas. Sterile tumor specimens were processed for tissue culture as described (1) Anti-C3-MHA (C3-MHA) Assay. The C3-MHA assay described by Irie et al. (7) was modified in the following way: EAC 14 cells were incubated with guinea pig C2 and C3 (Cordis Laboratories). After washing with Veronal buffer medium (VBM), the EAC 1423 cell suspension was incubated with a subagglutinating concentration of goat anti guinea pig C3 (Cappel Laboratories). Tumor cells were seeded in wells of 3040 microtest plates (Falcon Plastics) as described for MHA and IA assays (1, 2) . After incubation of target cells with serial dilutions of autologous serum at either 40 or 24°for 1 hr, the wells were washed three times with VBM/5% fetal bovine serum and once with VBM alone. To each well, 0.05 ml of a 1:50 dilution of preselected guinea pig serum was added as a source of complement and the mixture was incubated at 370 for 30 min. The wells were again washed as before. Then, 0.05 ml of 0.05% (vol/vol) suspension of indicator cells was added to each well and incubated at 370 for 30 min. After this final incubation, the plates were washed once with VBM and evaluated by light microscopy. Individual positive cells were scored as described for the IA assay (2). In each experiment, control wells incubated with VBM/5% fetal bovine serum alone were included; as a rule these had <1% positive cells. Antibody titer refers to the highest serum dilution that showed 10% positive cells.
Protein A (PA) Assay. For the preparation of PA indicator cells, staphylococcal protein A (Pharmacia Fine Chemicals) was conjugated to the surface of human 0+ erythrocytes with 0.01% CrC13. Indicator cells were washed twice in VBM and resuspended in VBM. After incubation of target cells with serial dilutions of autologous serum at 40 or 240, the wells were washed three times with Ca2+-and Mg2+-free phosphatebuffered saline (Pi/NaCI) containing 5% gamma globulin-free fetal bovine serum; 0.05 ml of a 0.2% (vol/vol) suspension of indicator cells was added to each well. After a 45-min incubation at 240, the wells were washed once in the same Pi/NaCl/ fetal bovine serum and evaluated under a light microscope. PA assays were evaluated according to the same criteria as C3-MHA assays.
RESULTS
Reactions of Autologous Sera with Surface Antigens of Cultured Astrocytoma Cells. Sera from 30 patients were tested for reactivity to cell surface antigens of autologous astrocytomas. In all but a few instances, each serum was tested in the four serological assays: MHA, IA, C3-MHA, and PA. (Table 1) . Autologous sera did not react with these cells in MHA, PA, or IA assays. However, reactions were observed in C3-MHA tests with sera from three patients (AA, AB, and AC). Sera from the two other patients tested (AD and BC) were negative. Fig. 2 illustrates the reactions of AC and BC sera with autologous fibroblasts and astrocytoma cells. Serum from patient AC reacted equally well with normal fibroblasts and astrocytoma cells, whereas serum from patient BC reacted with astrocytoma cells but not fibroblasts.
Absorption Analysis of Autologous Serum Reactivity for Astrocytoma Cells. In 15 cases, autologous serum reactivity was high enough in at least one of the four assays to permit analysis of the reaction by absorption tests. Fig. 3 illustrates individual absorption tests with sera from patients AC, BC, AJ, and AK. the AU, BD, and BI melanoma antigens representing class I antigens (1-3) , the AH melanoma antigen representing a class II antigen (2), and class III antigens being commonly detected by sera from melanoma patients (3) . Class III antigens are also the ones most commonly detected by sera from astrocytoma patients (Table 1) . Because antibodies to class III antigens are frequently not detectable in direct tests with autologous fibroblasts, even though the presence of class III antigens on fibroblasts is revealed by absorption tests, these antigens can be mistaken for tumor-specific antigens. For this reason, rigorous absorption analysis is essential to distinguish antigens belonging to class III from those belonging to class I or class II.
The class I antigens of astrocytomas and melanomas resemble the individually distinct or unique antigens demonstrable by transplantation techniques on various experimental tumors (see ref. 8) . It was once thought that these unique antigens were characteristic of chemically induced tumors and that virusinduced tumors had shared antigens that were common to all tumors induced by a particular virus. We now know that this distinction is not absolute; chemically induced tumors can have shared antigens and virus-induced tumors can express individually distinct antigens. The extensive polymorphism of individually distinct or class I antigens is a fascinating puzzle for tumor biologists. The nature of these antigens has been the subject of much speculation, with their origin being ascribed to host or viral genes that have been mutated, derepressed, or otherwise rearranged, or to epigenetic errors in membrane synthesis. The availability of serological reagents that detect these antigens in human melanoma and astrocytoma and in experimental tumors should make it possible to define their chemical nature and, by means of somatic cell hybrids, to ask whether class I antigens are specified by distinct chromosomal loci.
Two class II antigens have been defined by autologous typing of cultured human cancer cells: the AJ antigen of astrocytoma and the previously described AH antigen of melanoma (2) . In comparing the AJ and AH phenotypes of a series of melanomas, it became evident that these two antigenic systems were related; melanomas were either AJ+AH+ or AJ-AH-but not AJ+AH-or AJ-AH+. One possibility that could account for the sharing of an antigen by astrocytomas and melanomas comes from the fact that these tumors are derived from cells of neural crest origin. According to this view, the AJ and AH antigens represent serologically related differentiation antigens of neural crestderived tissues and this would be consistent with the finding that neuroblastomas also are AJ+. This possibility seems unlikely for two reasons: fetal brain (12-16 weeks' gestation) lacks AJ antigen; and sarcomas, which are of mesodermal origin, type AJ+. In this regard, it may be relevant that AJ astrocytoma showed marked sarcomatous changes; it is conceivable that this might have provided the immunogenic stimulus for the production of antibody to an antigen shared by sarcomas and neural crest-derived malignancies. Another possibility that cannot be excluded at present is that AJ antigen is related to a virus that is restricted to AJ+ tumors. Once again, the availability of serological probes that define class II antigens should permit us to gain insight into the genetic origin of these antigens.
From this study of astrocytomas and our continuing study of melanomas, it is clear that the simultaneous use of several serological test systems minimizes the risk of missing autologous serum reactivity. This can be ascribed to differences in the inherent sensitivity of the various techniques and to the fact that they detect different classes of immunoglobulins. For example, the reactivity of BC serum, which is detected by C3-MHA and PA assays, would have been missed if only MHA and IA tests had been performed. In addition, the AU melanoma antigen (1), which was originally defined by MHA, cannot be detected by IA, and the AH melanoma antigen (2), originally defined by IA, cannot be detected by MHA. Another advantage of using more than one assay is the possibility of detecting antibodies to different specificities in the same serum. This is what we observed in absorption analysis of sera from patient BC; PA assays detected a class I antigen and C3-MHA assays detected a class III antigen (Table 1) .
Because cultured cells form the basis for these serological studies of surface antigens of human cancer cells, a major impediment to future progress in this area is the general inability to grow many types of human cells, both normal and malignant, in tissue culture. In our experience, approximately 50% of astrocytomas and 20-30% of melanomas will propagate sufficiently to permit repeated serological testing of autologous sera. With other tumor types, such as breast, lung, and colon, serological study by autologous typing is possible in less than 5% of cases. Defining conditions for the successful culture of a greater proportion of human cancers and, wherever possible, the comparable normal cell population will be necessary before a comprehensive and meaningful classification of the surface antigens of human cancers can be achieved.
